Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**dextrose monohydrate + heparin sodium** is a sterile, nonpyrogenic solution for intravenous infusion, consisting of heparin sodium (an anticoagulant glycosaminoglycan usually derived from porcine intestinal mucosa) and hydrous dextrose USP in water for injection. Heparin inhibits reactions that lead to the clotting of blood and formation of fibrin clots both in vitro and in vivo, acting mainly by accelerating the interaction of antithrombin III with activated clotting factors (especially Factor Xa and thrombin), thereby blocking their actions[1][5][8]. Dextrose serves as an isotonic vehicle and energy source. This combination product is primarily indicated for the continuous intravenous infusion in situations requiring anticoagulant therapy, especially following initiation by IV heparin sodium. Clinical indications include prophylaxis and treatment of venous thrombosis and pulmonary embolism, atrial fibrillation with embolization, treatment of consumptive coagulopathies (DIC), prevention of clotting in surgery, and maintenance of patency in intravenous devices[1][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextrose monohydrate + heparin sodium.